Shuttle Pharmaceuticals Stock Revenue
| SHPH Stock | USD 0.85 0.02 2.30% |
Shuttle Pharmaceuticals fundamentals help investors to digest information that contributes to Shuttle Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Shuttle Stock. The fundamental analysis module provides a way to measure Shuttle Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shuttle Pharmaceuticals stock.
| Last Reported | Projected for Next Year |
Shuttle | Revenue |
Shuttle Pharmaceuticals Company Revenue Analysis
Shuttle Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Shuttle Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Shuttle Pharmaceuticals reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and about the same as Health Care (which currently averages 0.0) industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Shuttle Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shuttle Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shuttle Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Shuttle Pharmaceuticals by comparing valuation metrics of similar companies.Shuttle Pharmaceuticals is currently under evaluation in revenue category among its peers.
Shuttle Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Shuttle Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Shuttle Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Shuttle Pharmaceuticals' value.| Shares | Hrt Financial Llc | 2024-09-30 | 25.9 K | Tower Research Capital Llc | 2024-09-30 | 3.9 K | Federation Des Caisses Desjardins Du Quebec | 2024-09-30 | 63.0 | Renaissance Technologies Corp | 2024-06-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 0.0 | Ubs Group Ag | 2024-06-30 | 0.0 |
Shuttle Fundamentals
| Return On Equity | -1.86 | ||||
| Return On Asset | -0.62 | ||||
| Current Valuation | 3.52 M | ||||
| Shares Outstanding | 3.66 M | ||||
| Shares Owned By Insiders | 27.80 % | ||||
| Shares Owned By Institutions | 1.81 % | ||||
| Number Of Shares Shorted | 58.92 K | ||||
| Price To Book | 4.16 X | ||||
| EBITDA | (5.89 M) | ||||
| Net Income | (6.59 M) | ||||
| Cash And Equivalents | 50.44 K | ||||
| Total Debt | 1.09 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 0.03 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (5.58 M) | ||||
| Short Ratio | 0.25 X | ||||
| Earnings Per Share | (4.25) X | ||||
| Beta | 0.74 | ||||
| Market Capitalization | 3.12 M | ||||
| Total Asset | 5.95 M | ||||
| Retained Earnings | (15.49 M) | ||||
| Working Capital | 4.55 M | ||||
| Net Asset | 5.95 M |
About Shuttle Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shuttle Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shuttle Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shuttle Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Shuttle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Shuttle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Shuttle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Shuttle Pharmaceuticals Stock:Check out Shuttle Pharmaceuticals Piotroski F Score and Shuttle Pharmaceuticals Altman Z Score analysis. For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Shuttle Pharmaceuticals. If investors know Shuttle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Shuttle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.25) | Return On Assets (0.62) | Return On Equity (1.86) |
The market value of Shuttle Pharmaceuticals is measured differently than its book value, which is the value of Shuttle that is recorded on the company's balance sheet. Investors also form their own opinion of Shuttle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Shuttle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Shuttle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Shuttle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Shuttle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shuttle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Shuttle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.